Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969240 | 0.89 | ALDH1A1 (0.73) | ALDH1A1CA12CA2CA9LMNA | |
| SCHEMBL890725 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CA12CA2CA9PKM | |
| SCHEMBL7094852 | 0.85 | ALDH1A1 (0.79) | ALDH1A1CA12CA2CA9LMNA | |
| SCHEMBL3868630 | 0.85 | ALDH1A1 (0.71) | ALDH1A1LMNAPKMMEN1KMT2A | |
| SCHEMBL4951882 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CA12CA2CA9PKM | |
| SCHEMBL8484861 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CA12CA2CA9PKM | |
| SCHEMBL7093365 | 0.84 | ALDH1A1 (0.77) | ALDH1A1CA12CA2CA9LMNA | |
| SCHEMBL7097551 | 0.84 | ALDH1A1 (0.77) | ALDH1A1CA12CA2CA9LMNA | |
| SCHEMBL4815560 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CA12CA2CA9PKM | |
| SCHEMBL4812770 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CA12CA2CA9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7488731-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488731-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488731-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080027066-A1 | Arylpiperazinyl Compounds | EPIX DELAWARE, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027066-A1 | Arylpiperazinyl Compounds | EPIX DELAWARE, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027066-A1 | Arylpiperazinyl Compounds | EPIX DELAWARE, INC. | 2008-01-31 | — | — | US | disclosed |
| EP-1592425-A4 | NEW ARYLPIPERAZINYL COMPOUNDS | EPIX DELAWARE INC (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20070004742-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004742-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004742-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7153858-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1592425-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | Predix Pharmaceuticals Holdings, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069794-A9 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDING (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040220192-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004069794-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027066-A1 | Arylpiperazinyl Compounds | HTR5A, HTR1A, HTR2A | ALDH1A1 346/4885CA12 4873/4885CA2 4304/4885 |
| US-20070004742-A1 | Arylpiperazinyl compounds | HTR5A, HTR1A, HTR2A | ALDH1A1 346/4885CA12 4873/4885CA2 4304/4885 |
| US-20040220192-A1 | Arylpiperazinyl compounds | HTR5A, HTR1A, HTR2A | ALDH1A1 346/4885CA12 4873/4885CA2 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.